Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data

Abstract Trifluridine/tipiracil increases overall survival (OS) in patients with refractory, metastatic colorectal cancer (mCRC). A post hoc exploratory analysis of the RECOURSE randomized clinical trial (RCT) established two categories, a good prognosis corresponding to subjects having a low tumor...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Ana Fernández Montes, Alberto Carmona-Bayonas, Paula Jimenez-Fonseca, Francisca Vázquez Rivera, Nieves Martinez Lago, Marta Covela Rúa, Antía Cousillas Castiñeiras, Paula Gonzalez Villarroel, Juan De la Cámara Gómez, José Carlos Méndez Méndez, Carmen Carriles Fernández, Manuel Sanchez Cánovas, Teresa Garcia García
Format: article
Langue:EN
Publié: Nature Portfolio 2021
Sujets:
Medicine
R
Science
Q
Accès en ligne:https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b994
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Internet

https://doaj.org/article/79955248229f4b8ab9ff4d86bc53b994

Documents similaires